In mice, a promising new weight-loss medication called CPACC prevented weight gain in response to a high-fat, high-sugar diet.
The body’s metabolism is increased by CPACC, which aids in the more efficient breakdown of fats and sugars, according to researchers at the University of Texas Health Science Center in San Antonio.
The medication accomplishes this by preventing magnesium from entering the mitochondria, the cell’s power plant and primary source of cellular metabolic activity.
After 20 weeks of treatment with CPACC, the mice remained thin and had significantly reduced levels of cholesterol and glucose compared to the control group.
Without CPACC, high-fat-diet-fed mice gained weight and had elevated cholesterol and glucose levels.
According to the study authors, CPACC has the potential to be a “game-changer” for those who have difficulty losing weight.
Current weight reduction medications like Ozempic and Wegovy target insulin response, but this operates in a different way. CPACC could be given orally and would not necessitate dietary changes.
The team has applied for a patent on CPACC and hopes to start human trials within the next few years.
Proponents of CPACC see it as a potential new tool in the fight against obesity. Some forms of cancer, cardiovascular disease, and diabetes type 2 are all increased by obesity.
As the study’s principal investigator, Dr. Madesh Muniswamy of the University of Texas’s Department of Biochemistry and Molecular Biology, put it: “It would have a profound effect if there were a treatment that could reduce the risk of cardiovascular disorders like heart attack and stroke, as well as the chance of liver cancer, which can develop as a result of fatty liver disease.”
“We will continue its development.”
